Acute Coronary Syndrome and its Antithrombotic Treatment: Focus on Aspirin and Clopidogrel Resistance

Bonvini, Robert F.; Reny, Jean-Luc; Mach, Fran├žois; Zeller, Thomas; Fontana, Pierre
April 2009
Current Vascular Pharmacology;Apr2009, Vol. 7 Issue 2, p198
Academic Journal
Cardiovascular diseases are the most common cause of mortality and morbidity accounting for more than 40% of total mortality in Western countries, most of which is due to acute coronary syndromes (ACS), including ST and non- ST elevation myocardial infarction. An optimal pharmacological approach in these patients is of major importance with a particular emphasis on the antiplatelet regimen, which remains the cornerstone of the initial ACS treatment at hospital admission and during percutaneous coronary interventions (PCI). This review briefly discusses the pathogenesis of ACS, and updates the available pharmacological antithrombotic strategies with a particular focus on aspirin and clopidogrel resistance, which has caused major concern, especially in the modern era of interventional cardiology. Persistent platelet reactivity despite aspirin or clopidogrel intake is probably a risk factor for the recurrence of ischemic events. Despite a lack of uniformly accepted definitions of aspirin and clopidogrel resistance, we provide an objective description of what is already proved and what remains to be established. In clopidogrel poor-responders, preliminary data suggest that increasing the loading dose might be beneficial prior to PCI, while trials on the potential benefit of an increased maintenance dose after PCI are ongoing. Overall, data on the mechanisms and the management of platelet hyperactivity or antiplatelet drug biological resistance are still scarce and further studies are needed.


Related Articles

  • Is ticlopidine more effective than aspirin in preventing adverse cardiovascular events after myocardial infarction (MI)? Olson, John; Huntington, Jane // Journal of Family Practice;Jul2001, Vol. 50 Issue 7, p623 

    The article discusses research being done on the comparison of ticlopidine with aspirin after myocardial infarction (MI). It references to a study by D. Scrutinio et al published in the 2001 issue of the "Journal of American College Cardiology." The study found that ticlopidine is as effective...

  • Low-dose acetylsalicyclic acid: risks of haemorrhage?  // WHO Drug Information;1999, Vol. 13 Issue 2, p66 

    Examines the effectiveness of low-dose acetylsalicylic acid (ASA) as an antithrombosis drug for secondary prevention in patients surviving myocardial infarction. Reduction of the risk of recurring transient ischemic attacks, stroke or death in men; Risk of intracerebral hemorrhage; Association...

  • Antithrombotic Therapy after Myocardial Infarction. Becker, Richard C. // New England Journal of Medicine;9/26/2002, Vol. 347 Issue 13, p1019 

    Editorial. Stresses the importance of antithrombotic therapy and other secondary-prevention strategies after myocardial infarction. The potential role of oral anticoagulant therapy as secondary prevention; The importance of coagulation proteases and thrombin generation on nonplatelet surfaces;...

  • Long-Term, Low-Dose Aspirin Therapy.  // HealthFacts;Nov2006, Vol. 31 Issue 11, p3 

    The article discusses research on the bleeding risk of lifelong regimen of Plavix to prevent a heart attack or stroke. According to researchers at the Veterans Affairs Medical Center in San Francisco, California, the odds of harm of anti-clotting drug Plavix were low. A trial involving a...

  • Beware of clot buster plus aspirin.  // Consumer Reports on Health;Aug2006, Vol. 18 Issue 8, p6 

    The article reports on the risk of adding an anti-clotting drug clopidogrel to aspirin for the prevention of heart attack and stroke. Television advertisements have recognized the benefits of adding clopidogrel to aspirin for preventing heart attack, but, for most people the combination provide...

  • A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction... Julian, D.G.; Chamberlain, D.A. // BMJ: British Medical Journal (International Edition);12/07/96, Vol. 313 Issue 7070, p1429 

    Compares aspirin with anticoagulation with regard to risk of cardiac death and re-infarction in patients who received anistreplase thrombolysis for myocardial infarction. Absence of evidence in the incidence of cardiac events found between the two treatment groups; Higher incidence of severe...

  • antiplatelet drugs. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p58 

    An encyclopedia entry for "antiplatelet drugs" is presented. They refer to drugs that decrease the tendency of platelets to stick together to form blood clots when blood flow in the arteries is disrupted. They reduce the risk of thromboembolism, which can lead to potentially fatal disorders such...

  • Perioperative Cardiovascular Complications. Hoyle, Brian; Sessler, Daniel I.; Devereaux, Philip J.; Alonso-Coello, Pablo // MD Conference Express;Aug2015, Vol. 15 Issue 21, p17 

    Most postoperative myocardial infarctions are detected as asymptomatic elevated troponin. Aspirin appears ineffective in preventing postoperative myocardial infarction following noncardiac surgery, but it may have a protective role before surgery. Antithrombotic therapy may be used for...

  • The increasing burden of cardiovascular disease: the role of aspirin in treatment and prevention. Hennekens, Charles H.; Malecki, Jean M.; Howell, James A. // Caribbean Health;Jun2001, Vol. 4 Issue 3, p8 

    The article examines the role of aspirin in the treatment and prevention of cardiovascular disease. It is noted that aspirin has the best benefit-to-risk and benefit-to-cost ratio of any treatment for acute myocardial infarction. Data support the benefits of aspirin in patients with atrial...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics